Taribavirin: A potential alternative to ribavirin

Future Virology

Volumn 4, Issue 2, 2009, Pages 113-120

  Poordad, Fred F ^a   Chee, Grace ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Erythropoietin; Genotype; HCV; Hemolytic anemia; Hepatitis C; Peg IFN; Pegylated interferon; RBV; Ribavirin; Taribavirin; TBV

Indexed keywords

BOCEPREVIR; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TARIBAVIRIN; TELAPREVIR;

ANEMIA; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEPATITIS C VIRUS; HUMAN; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

HEPATITIS C VIRUS; TULIP BREAKING VIRUS;

EID: 70349199772     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460794.4.2.113     Document Type: Article

References (22)

1. Fried MW, Shiffman ML, Reddy KR et al.: Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347(13), 975-982 (2002).
2. Lindsay KL, Trepo C, Heintges T et al.: A randomized, double-blind trial comparing pegylated interferon α-2b to interferon α-2b as initial treatment for chronic hepatitis C. Hepatology 34(2), 395-403 (2001).
3. Kieffer TL, Sarrazin C, Miller JS et al.: Telaprevir and pegylated interferon α-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 46, 631-639 (2007).
4. Pockros PJ, Shiffman M, Schiff ER et al.: Epoetin-α improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology 40(6), 1450-1458 (2004).
5. Edlin BR: Five million Americans infected with the hepatitis C virus: a corrected estimate. Hepatology 42(Suppl. 1), 213A (2005).
6. Strader DB, Wright T, Thomas DL, Seeff LB: Diagnosis, management, and treatment of hepatitis C. Hepatology 39(4), 1147-1171 (2004).
7. Manns MP, McHutchison JG, Gordon SC et al.: Peginterferon α-2b plus ribavirin compared wiuh interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358(9286), 958-965 (2001).
8. Sulkowski M, Lawitz E, Shiffman MI, et al.: Final results of the IDEAL (individualized dosing efficacy versus flat dosing to assess optimal pegylated interferon therapy) Phase IIIb study. Presented at: The 43rd Annual Meeting of the European Association for the Study of the Liver. Milan, Italy, 23-27 April 2008.
9. Crespo M, Sauleda S, Esteban JI et al.: Peginterferon α-2b plus ribavirin vs interferon α-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients. Viral Hepat. 14(4), 228-238 (2007).
10. Oton E, Barcena R, Moreno-Planas JM et al.: Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose PEG-interferon and ribavirin. Am. J. Transplant. 6(10), 2348-2355 (2006).
11. Mchutchison JG, Everson GT, Gordon SC et al.: PROVEI: Results from a Phase 2 study of telaprevir with peginterferon α-2a and ribavirin in treatment-naive subjects with hepatitis C. Presented at: The 43rd Annual Meeting of the European Association for the Study of the Liver. Milan, Italy, 23-27 April 2008.
12. Zeuzem S, Hezode C, Ferenci P et al.: Telaprevir in combination with peginterferon-α-2a with or without ribavirin in the treatment of chronic hepatitis C: final results of the PROVE2 study. Hepatology 48(Suppl. 4), A243 (2008).
13. Kwo P, Lawitz E, McCone J et al.: Interim results from HCV SPRINT-1: RVR/EVR from Phase 2 study of boceprevir plus peginterferon α-2b/ribavirin in treatment-naive subjects with genotype-1 CHC. Presented at: The 43rd Annual Meeting of the European Association for the Study of the Liver. Milan, Italy, 23-27 April 2008.
14. Wu JZ, Walker H, Lau JY et al.: Activation and deactivation of a broad-spectrum antiviral drug by a single enzyme: adenosine deaminase catalyzes two consecutive deamination reactions. Antimicrob. Agents Chemother. 47(1), 426-431 (2003).
15. Wu JZ, Lin C, Hong Z: Ribavirin, viramidine and adenosine-deaminase-catalysed drug activation: implication for nucleoside prodrug design. J. Antimicrob. Chemother. 52(4), 543-546 (2003).
16. 14Cribavirin in rat and monkey red blood cells and liver. Antimicrob. Agents Chemother. 48(5), 1872-1875 (2004).
17. Aora S, Xu C, Teng A et al.: Ascending multiple-dose pharmacokinetics of viramidine, a prodrug of ribavirin, in adult subjects with compensated hepatitis C infection. J. Clin. Pharmacol. 45(3), 275-285 (2005).
18. Lin CC, Philips L, Xu C, Yeh LT: Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers. J. Clin. Pharmacol. 44(3), 265-275 (2004).
19. Gish RG, Arora S, Reddy KR et al: Virological response and safety outcomes in therapy-naive patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon α-2a: a randomized, Phase 2 study. J. Hepatol. 47(1), 51-59 (2007).
20. Benhamou Y, Pockros P, Rodriguez-Torres M et al.: The safety and efficacy of viramidine plus PegIFN α-2b versus ribavirin plus PegIFN α-2b in therapy-naive patients infected with HCV: Phase 3 results (VISER1). J. Hepatol. 44, S273 (2006).
21. Poordad F, Lawitz, E, Chun E, Hammond J: Taribavirin comparable in efficacy to ribavirin and results in less anaemia in patients with chronic hepatitis c. Presented at: The 43rd Annual Meeting of the European Association for the Study of the Liver. Milan, Italy, 23-27 April 2008.
22. Lawitz E, Muir AJ, Poordad F et al.: Treatment week 24 results of weight-based taribavirin versus weight-based ribavirin, both with peginterferon α-2b, in naive chronic hepatitis C, genotype 1 patients. Hepatology 48(Suppl. 4), A272 (2008).